•
Mar 31, 2023
Amicus Therapeutics Q1 2023 Earnings Report
Amicus Therapeutics reported strong Q1 2023 results with revenue growth and progress towards regulatory approvals and non-GAAP profitability.
Key Takeaways
Amicus Therapeutics announced a strong start to 2023, with Galafold driving revenue growth and progress made towards the approval and launch of AT-GAA. The company is on track to achieve non-GAAP profitability in the second half of the year.
Q1 2023 revenue grew 14% at CER to $86.3 million.
On track to deliver full-year 2023 Galafold revenue growth of 12%-17% at CER.
U.S. FDA pre-approval inspection for AT-GAA complete; approval expected in Q3 2023.
European launch of Pombiliti®+Opfolda® expected in Q3 2023.
Amicus Therapeutics
Amicus Therapeutics
Forward Guidance
Amicus Therapeutics is focused on growing Galafold, securing regulatory approvals and launching AT-GAA, and achieving non-GAAP profitability in the second half of 2023.